🇺🇸 FDA
Patent

US 12404497

Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof

granted A61KA61K35/766A61K38/2013

Quick answer

US patent 12404497 (Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof) held by Medicenna Therapeutics Inc. expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medicenna Therapeutics Inc.
Grant date
Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K35/766, A61K38/2013, A61P, A61P35/00